Literature DB >> 9269759

Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans.

D Pajkrt1, A Manten, T van der Poll, M M Tiel-van Buul, J Jansen, J Wouter ten Cate, S J van Deventer.   

Abstract

In this double-blind, cross-over, placebo-controlled, randomized study, two groups of eight healthy male volunteers were challenged with endotoxin (4 ng/kg) on two occasions, once in conjunction with placebo and once with granulocyte colony-stimulating factor (G-CSF; 5 microg/kg). In group 1, G-CSF was administered intravenously 2 hours before endotoxin challenge; in group 2, G-CSF was administered subcutaneously 24 hours before endotoxin challenge. In group 1, G-CSF significantly enhanced the release of tumor necrosis factor (TNF), interleukin-6 (IL-6), IL-8, IL-1 receptor antagonist (IL-1ra), and soluble TNF receptors. In group 2, G-CSF significantly reduced IL-8 concentrations and modestly attenuated TNF and IL-6 levels. In this group, IL-1ra and soluble TNF receptors were enhanced by G-CSF pretreatment and lipopolysaccharide (LPS)-induced soluble TNF receptor release was further augmented, whereas LPS-induced IL-1ra concentrations remained unaltered. Both pretreatments with G-CSF increased LPS-induced peripheral neutrophilia; the expression of CD11b, CD18, and CD67; and the release of elastase and lactoferrin. Both pretreatments also down-regulated neutrophil L-selectin expression and prevented the endotoxin-induced pulmonary neutrophil accumulation during the first 2 hours after endotoxin challenge. These data indicate that two different pretreatments with G-CSF result in differential effects on LPS-induced cytokine release but similar effects on LPS-induced neutrophil activation and changes in expression of cell surface molecules. Finally, regardless of the effects of G-CSF on LPS-induced cytokine release, G-CSF blocks LPS-induced pulmonary granulocyte accumulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9269759

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  New insights into the biology of the acute phase response.

Authors:  A F Suffredini; G Fantuzzi; R Badolato; J J Oppenheim; N P O'Grady
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

2.  The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans.

Authors:  P E Dekkers; T ten Hove; F N Lauw; H R Koene; P Lumley; S J van Deventer; T van der Poll
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

3.  Delayed resolution of lung inflammation in Il-1rn-/- mice reflects elevated IL-17A/granulocyte colony-stimulating factor expression.

Authors:  Kristin M Hudock; Yuhong Liu; Junjie Mei; Roberta C Marino; Jason E Hale; Ning Dai; G Scott Worthen
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-16       Impact factor: 6.914

Review 4.  Toward improving mucosal barrier defenses: rhG-CSF plus IgG antibody.

Authors:  Aryeh Simmonds; Edmund F LaGamma
Journal:  Indian J Pediatr       Date:  2006-11       Impact factor: 1.967

Review 5.  Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction.

Authors:  Hiroyuki Takano; Yingjie Qin; Hiroshi Hasegawa; Kazutaka Ueda; Yuriko Niitsuma; Masashi Ohtsuka; Issei Komuro
Journal:  J Mol Med (Berl)       Date:  2006-01-17       Impact factor: 4.599

6.  Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission.

Authors:  Manfred Weiss; Sami Voglic; Britt Harms-Schirra; Ingrid Lorenz; Britta Lasch; Kristoffel Dumon; Wilhelm Gross-Weege; Elisabeth Marion Schneider
Journal:  Intensive Care Med       Date:  2003-04-08       Impact factor: 17.440

7.  Regulation of systemic and local neutrophil responses by G-CSF during pulmonary Pseudomonas aeruginosa infection.

Authors:  Alyssa D Gregory; Lisa A Hogue; Thomas W Ferkol; Daniel C Link
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

8.  Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery.

Authors:  Christian Schneider; Sonja von Aulock; Siegfried Zedler; Christian Schinkel; Thomas Hartung; Eugen Faist
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

9.  Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis.

Authors:  Christian T Brandt; Jens D Lundgren; Søren Peter Lund; Niels Frimodt-Møller; Thomas Christensen; Thomas Benfield; Frank Espersen; David M Hougaard; Christian Østergaard
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Effects of granulocyte-colony stimulating factor on peritoneal defense mechanisms and bacterial translocation after administration of systemic chemotherapy in rats.

Authors:  Celal Cerci; Cagri Ergin; Erol Eroglu; Canan Agalar; Fatih Agalar; Sureyya Cerci; Mahmut Bulbul
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.